Regeneron Pharmaceuticals Earnings Estimate
| REGN Stock | USD 890.68 15.86 1.75% |
Regeneron |
Regeneron Pharmaceuticals Earnings Estimation Breakdown
The calculation of Regeneron Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Regeneron Pharmaceuticals is estimated to be 10.1 with the future projection ranging from a low of 8.56 to a high of 11.62. Please be aware that this consensus of annual earnings estimates for Regeneron Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
8.56 Lowest | Expected EPS | 11.62 Highest |
Regeneron Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Regeneron Pharmaceuticals' value are higher than the current market price of the Regeneron Pharmaceuticals stock. In this case, investors may conclude that Regeneron Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Regeneron Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2024 | Current EPS (TTM) | |
| 26 | 89.89% | 11.86 | 10.1 | 34.81 |
Regeneron Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of Regeneron Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Regeneron Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Regeneron Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Regeneron Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Regeneron Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Regeneron Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.Regeneron Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Regeneron Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-03-13 | 2023-12-31 | 10.73 | 11.86 | 1.13 | 10 | ||
2023-11-02 | 2023-09-30 | 10.72 | 11.59 | 0.87 | 8 | ||
2023-08-03 | 2023-06-30 | 9.84 | 10.24 | 0.4 | 4 | ||
2023-05-04 | 2023-03-31 | 9.56 | 10.09 | 0.53 | 5 | ||
2023-02-03 | 2022-12-31 | 10.03 | 12.56 | 2.53 | 25 | ||
2022-11-03 | 2022-09-30 | 9.48 | 11.14 | 1.66 | 17 | ||
2022-08-03 | 2022-06-30 | 8.84 | 9.77 | 0.93 | 10 | ||
2022-05-04 | 2022-03-31 | 9.74 | 8.93 | -0.81 | 8 | ||
2022-02-04 | 2021-12-31 | 18.35 | 21.32 | 2.97 | 16 | ||
2021-11-04 | 2021-09-30 | 10.1 | 14.37 | 4.27 | 42 | ||
2021-08-05 | 2021-06-30 | 17.53 | 25.8 | 8.27 | 47 | ||
2021-05-06 | 2021-03-31 | 9 | 9.89 | 0.89 | 9 | ||
2021-02-05 | 2020-12-31 | 8.39 | 9.53 | 1.14 | 13 | ||
2020-11-05 | 2020-09-30 | 7.14 | 8.36 | 1.22 | 17 | ||
2020-08-05 | 2020-06-30 | 5.98 | 7.16 | 1.18 | 19 | ||
2020-05-05 | 2020-03-31 | 6.13 | 6.6 | 0.47 | 7 | ||
2020-02-06 | 2019-12-31 | 6.91 | 7.5 | 0.59 | 8 | ||
2019-11-05 | 2019-09-30 | 6.36 | 6.67 | 0.31 | 4 | ||
2019-08-06 | 2019-06-30 | 5.41 | 6.02 | 0.61 | 11 | ||
2019-05-07 | 2019-03-31 | 5.47 | 4.45 | -1.02 | 18 | ||
2019-02-06 | 2018-12-31 | 5.6 | 6.84 | 1.24 | 22 | ||
2018-11-06 | 2018-09-30 | 5.13 | 5.87 | 0.74 | 14 | ||
2018-08-02 | 2018-06-30 | 4.7 | 5.45 | 0.75 | 15 | ||
2018-05-03 | 2018-03-31 | 4.35 | 4.67 | 0.32 | 7 | ||
2018-02-08 | 2017-12-31 | 4.53 | 5.23 | 0.7 | 15 | ||
2017-11-08 | 2017-09-30 | 3.85 | 3.99 | 0.14 | 3 | ||
2017-08-03 | 2017-06-30 | 3.17 | 4.17 | 1.0 | 31 | ||
2017-05-04 | 2017-03-31 | 3.06 | 2.92 | -0.14 | 4 | ||
2017-02-09 | 2016-12-31 | 3.03 | 3.04 | 0.01 | 0 | ||
2016-11-04 | 2016-09-30 | 2.71 | 3.13 | 0.42 | 15 | ||
2016-08-04 | 2016-06-30 | 2.65 | 2.82 | 0.17 | 6 | ||
2016-05-05 | 2016-03-31 | 2.58 | 2.57 | -0.01 | 0 | ||
2016-02-09 | 2015-12-31 | 3.36 | 2.83 | -0.53 | 15 | ||
2015-11-04 | 2015-09-30 | 3.2 | 3.47 | 0.27 | 8 | ||
2015-08-04 | 2015-06-30 | 2.77 | 2.89 | 0.12 | 4 | ||
2015-05-07 | 2015-03-31 | 2.68 | 2.88 | 0.2 | 7 | ||
2015-02-10 | 2014-12-31 | 2.82 | 2.79 | -0.03 | 1 | ||
2014-11-04 | 2014-09-30 | 2.57 | 2.52 | -0.05 | 1 | ||
2014-08-05 | 2014-06-30 | 2.29 | 2.47 | 0.18 | 7 | ||
2014-05-08 | 2014-03-31 | 2.2 | 2.26 | 0.06 | 2 | ||
2014-02-11 | 2013-12-31 | 0.98 | 0.86 | -0.12 | 12 | ||
2013-11-05 | 2013-09-30 | 0.9 | 1.25 | 0.35 | 38 | ||
2013-08-06 | 2013-06-30 | 0.88 | 0.79 | -0.09 | 10 | ||
2013-05-03 | 2013-03-31 | 0.98 | 0.9 | -0.08 | 8 | ||
2013-02-14 | 2012-12-31 | 1.1 | 1.22 | 0.12 | 10 | ||
2012-10-24 | 2012-09-30 | 0.95 | 1.72 | 0.77 | 81 | ||
2012-07-25 | 2012-06-30 | 0.27 | 0.7 | 0.43 | 159 | ||
2012-04-26 | 2012-03-31 | -0.23 | 0.16 | 0.39 | 169 | ||
2012-02-13 | 2011-12-31 | -0.6 | -0.54 | 0.06 | 10 | ||
2011-10-27 | 2011-09-30 | -0.76 | -0.68 | 0.08 | 10 | ||
2011-07-28 | 2011-06-30 | -0.41 | -0.69 | -0.28 | 68 | ||
2011-05-03 | 2011-03-31 | -0.36 | -0.49 | -0.13 | 36 | ||
2011-02-17 | 2010-12-31 | -0.32 | -0.17 | 0.15 | 46 | ||
2010-10-28 | 2010-09-30 | -0.34 | -0.41 | -0.07 | 20 | ||
2010-07-28 | 2010-06-30 | -0.37 | -0.31 | 0.06 | 16 | ||
2010-04-29 | 2010-03-31 | -0.49 | -0.38 | 0.11 | 22 | ||
2010-02-18 | 2009-12-31 | -0.34 | -0.46 | -0.12 | 35 | ||
2009-11-03 | 2009-09-30 | -0.21 | -0.01 | 0.2 | 95 | ||
2009-08-04 | 2009-06-30 | -0.28 | -0.19 | 0.09 | 32 | ||
2009-04-30 | 2009-03-31 | -0.31 | -0.22 | 0.09 | 29 | ||
2009-02-26 | 2008-12-31 | -0.3 | -0.4 | -0.1 | 33 | ||
2008-11-04 | 2008-09-30 | -0.32 | -0.27 | 0.05 | 15 | ||
2008-07-31 | 2008-06-30 | -0.3 | -0.23 | 0.07 | 23 | ||
2008-05-01 | 2008-03-31 | -0.32 | -0.15 | 0.17 | 53 | ||
2008-02-27 | 2007-12-31 | -0.47 | -0.19 | 0.28 | 59 | ||
2007-11-06 | 2007-09-30 | -0.3 | -0.54 | -0.24 | 80 | ||
2007-08-01 | 2007-06-30 | -0.43 | -0.41 | 0.02 | 4 | ||
2007-05-02 | 2007-03-31 | -0.5 | -0.46 | 0.04 | 8 | ||
2007-03-01 | 2006-12-31 | -0.51 | -0.51 | 0.0 | 0 | ||
2006-11-06 | 2006-09-30 | -0.56 | -0.48 | 0.08 | 14 | ||
2006-08-03 | 2006-06-30 | -0.56 | -0.41 | 0.15 | 26 | ||
2006-05-03 | 2006-03-31 | -0.61 | -0.36 | 0.25 | 40 | ||
2006-02-24 | 2005-12-31 | -0.65 | -0.53 | 0.12 | 18 | ||
2005-11-03 | 2005-09-30 | -0.59 | -0.52 | 0.07 | 11 | ||
2005-08-04 | 2005-06-30 | -0.51 | -0.38 | 0.13 | 25 | ||
2005-04-28 | 2005-03-31 | -0.28 | -0.07 | 0.21 | 75 | ||
2005-02-22 | 2004-12-31 | -0.36 | 0.05 | 0.41 | 113 | ||
2004-10-28 | 2004-09-30 | -0.4 | -0.2 | 0.2 | 50 | ||
2004-07-26 | 2004-06-30 | -0.3 | -0.26 | 0.04 | 13 | ||
2004-04-26 | 2004-03-31 | -0.46 | 1.06 | 1.52 | 330 | ||
2004-02-23 | 2003-12-31 | -0.53 | -0.35 | 0.18 | 33 | ||
2003-10-29 | 2003-09-30 | -0.54 | -0.52 | 0.02 | 3 | ||
2003-08-01 | 2003-06-30 | -0.6 | -0.58 | 0.02 | 3 | ||
2003-05-05 | 2003-03-31 | -0.85 | -0.68 | 0.17 | 20 | ||
2003-01-30 | 2002-12-31 | -0.85 | -0.81 | 0.04 | 4 | ||
2002-10-31 | 2002-09-30 | -0.78 | -0.75 | 0.03 | 3 | ||
2002-07-30 | 2002-06-30 | -0.64 | -0.69 | -0.05 | 7 | ||
2002-04-29 | 2002-03-31 | -0.62 | -0.58 | 0.04 | 6 | ||
2002-01-31 | 2001-12-31 | -0.62 | -0.65 | -0.03 | 4 | ||
2001-10-22 | 2001-09-30 | -0.55 | -0.46 | 0.09 | 16 | ||
2001-07-31 | 2001-06-30 | -0.52 | -0.34 | 0.18 | 34 | ||
2001-05-01 | 2001-03-31 | -0.43 | -0.35 | 0.08 | 18 | ||
2001-01-25 | 2000-12-31 | -0.34 | -0.23 | 0.11 | 32 | ||
2000-10-24 | 2000-09-30 | -0.3 | -0.09 | 0.21 | 70 | ||
2000-07-27 | 2000-06-30 | -0.13 | -0.08 | 0.05 | 38 | ||
2000-04-28 | 2000-03-31 | -0.12 | -0.23 | -0.11 | 91 | ||
2000-02-04 | 1999-12-31 | -0.21 | -0.04 | 0.17 | 80 | ||
1999-10-28 | 1999-09-30 | -0.2 | -0.16 | 0.04 | 20 | ||
1999-07-30 | 1999-06-30 | -0.25 | -0.25 | 0.0 | 0 | ||
1997-08-01 | 1997-06-30 | -0.21 | -0.16 | 0.05 | 23 | ||
1997-05-06 | 1997-03-31 | -0.38 | -0.23 | 0.15 | 39 | ||
1997-02-05 | 1996-12-31 | -0.33 | -0.32 | 0.01 | 3 | ||
1996-10-23 | 1996-09-30 | -0.34 | -0.35 | -0.01 | 2 | ||
1996-07-29 | 1996-06-30 | -0.4 | -0.31 | 0.09 | 22 | ||
1996-05-03 | 1996-03-31 | -0.36 | -0.35 | 0.01 | 2 | ||
1996-02-05 | 1995-12-31 | -0.3 | -0.38 | -0.08 | 26 | ||
1995-11-14 | 1995-09-30 | -0.39 | -0.32 | 0.07 | 17 | ||
1995-08-01 | 1995-06-30 | -0.24 | -0.22 | 0.02 | 8 | ||
1995-05-03 | 1995-03-31 | -0.35 | -0.22 | 0.13 | 37 | ||
1995-02-13 | 1994-12-31 | -0.39 | -0.3 | 0.09 | 23 | ||
1994-10-31 | 1994-09-30 | -0.36 | -0.21 | 0.15 | 41 | ||
1994-08-03 | 1994-06-30 | -0.58 | -0.54 | 0.04 | 6 |
About Regeneron Pharmaceuticals Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Regeneron Pharmaceuticals earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Regeneron Pharmaceuticals estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Regeneron Pharmaceuticals fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | 27.3 B | 28.6 B | |
| Retained Earnings Total Equity | 26.8 B | 28.1 B | |
| Earnings Yield | 0.04 | 0.04 | |
| Price Earnings Ratio | 23.70 | 24.89 | |
| Price Earnings To Growth Ratio | (2.78) | (2.64) |
Currently Active Assets on Macroaxis
When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Regeneron Stock analysis
When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.03) | Earnings Share 34.81 | Revenue Per Share 122.935 | Quarterly Revenue Growth 0.006 | Return On Assets 0.0849 |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.